R
Ross C. Donehower
Researcher at Johns Hopkins University
Publications - 233
Citations - 32588
Ross C. Donehower is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pharmacokinetics & Chemotherapy. The author has an hindex of 72, co-authored 229 publications receiving 28457 citations. Previous affiliations of Ross C. Donehower include Johns Hopkins University School of Medicine & National Institutes of Health.
Papers
More filters
Journal Article
Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Eric K. Rowinsky,Philip J. Burke,Judith E. Karp,Robert W. Tucker,David S. Ettinger,Ross C. Donehower +5 more
TL;DR: The maximum tolerated doses and recommended Phase II doses for taxol, limited by nonhematological toxicity and administered as a 24-h i.v. infusion to patients with refractory leukemias, are 390 and 315 mg/m2.
Journal Article
Absorption, Metabolism, and Excretion of 14C-Temozolomide following Oral Administration to Patients with Advanced Cancer
Sharyn D. Baker,Sharyn D. Baker,Mark A. Wirth,Paul Statkevich,Pascale Reidenberg,Kevin B. Alton,S E Sartorius,Margaret Dugan,David L. Cutler,Vijay Batra,Louise B. Grochow,Ross C. Donehower,Eric K. Rowinsky +12 more
TL;DR: A first- order absorption, one-compartment linear model, which included first-order formation ofMTIC from TMZ and elimination of MTIC via degradation to AIC, and a peripheral distribution compartment for AIC adequately described the plasma TMZ, MTIC,and AIC concentrations, demonstrated rapid oral absorption and high systemic availability.
Journal ArticleDOI
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
Eric K. Rowinsky,V Chaudhry,Arlene A. Forastiere,S E Sartorius,David S. Ettinger,Louise B. Grochow,B G Lubejko,D R Cornblath,Ross C. Donehower +8 more
TL;DR: Although this Taxol dose is nearly 85% higher than the dose that can be combined with cisplatin in the absence of G-CSF, this high-dose regimen should not be used outside the investigational setting until a dose-response relationship has been demonstrated for Taxol in randomized clinical trials.
Journal ArticleDOI
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.
Tian Li Wang,Luis A. Diaz,Katharine E. Romans,Alberto Bardelli,Saurabh Saha,Gennaro Galizia,Michael A. Choti,Ross C. Donehower,Giovanni Parmigiani,Ie Ming Shih,Christine A. Iacobuzio-Donahue,Kenneth W. Kinzler,Bert Vogelstein,Christoph Lengauer,Victor E. Velculescu +14 more
TL;DR: It is suggested that genetic amplification of TYMS is a major mechanism of 5-FU resistance in vivo and have important implications for the management of colorectal cancer patients with recurrent disease.
Journal Article
Phase I trial of taxol in patients with advanced cancer.
TL;DR: The frequent occurrence early in the study of acute cardiovascular and pulmonary toxicity suggestive of hypersensitivity reactions was decreased in frequency and severity by prolonging the infusions and premedication with corticosteroids and antihistamines.